Tvardi Therapeutics’ (TVRD) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings reiterated their sell (e+) rating on shares of Tvardi Therapeutics (NASDAQ:TVRD) in a research note issued to investors on Tuesday,Weiss Ratings reports.

Several other brokerages also recently weighed in on TVRD. BTIG Research cut their target price on shares of Tvardi Therapeutics from $55.00 to $15.00 and set a “buy” rating for the company in a research note on Monday. Barclays set a $5.00 price objective on shares of Tvardi Therapeutics and gave the company an “equal weight” rating in a research note on Monday. Raymond James Financial downgraded shares of Tvardi Therapeutics from an “outperform” rating to a “market perform” rating in a research note on Tuesday. Piper Sandler downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Finally, Cantor Fitzgerald downgraded shares of Tvardi Therapeutics from an “overweight” rating to a “neutral” rating in a research note on Monday. Three analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Tvardi Therapeutics presently has an average rating of “Hold” and an average price target of $55.50.

Tvardi Therapeutics Price Performance

Shares of TVRD stock opened at $6.48 on Tuesday. The company has a 50-day moving average price of $30.57. Tvardi Therapeutics has a twelve month low of $5.65 and a twelve month high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last announced its earnings results on Thursday, August 14th. The company reported ($1.00) earnings per share for the quarter, missing the consensus estimate of ($0.51) by ($0.49). Tvardi Therapeutics had a negative net margin of 678.79% and a negative return on equity of 565.83%.

Institutional Trading of Tvardi Therapeutics

A number of institutional investors have recently modified their holdings of TVRD. Slate Path Capital LP purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $16,427,000. 683 Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $4,107,000. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $2,617,000. Marshall Wace LLP purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $583,000. Finally, Bank of America Corp DE purchased a new stake in shares of Tvardi Therapeutics during the 2nd quarter worth about $399,000. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells.